治疗心力衰竭的新疗法:专注于cGMP信号传递
Supachoke Mangmool1, Ratchanee Duangrat1, Warisara Parichatikanond2
1Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
International journal of molecular sciences
|August 26, 2023
概括
新的心力衰竭 (HF) 药物向循环氨酸单酸 (cGMP) 信号通路. 这些新型疗法对心脏衰竭的减少射出分数 (HFrEF) 和保存射出分数 (HFpEF) 都有前景.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 目前的心力衰竭 (HF) 治疗主要有利于减少喷射率 (HFrEF) 的患者.
- 新型药物类正在出现,具有独特的HF干预机制.
- 循环氨酸单酸盐 (cGMP) 信号传输在心肌功能中起着至关重要的作用.
研究的目的:
- 在高频的背景下,审查cGMP信号传递的分子途径.
- 总结新兴药物类别的临床试验,针对治疗HF的cGMP信号.
- 突出针对HFrEF和HFpEF的cGMP向药物的潜力.
主要方法:
- 对当前和新兴的HF疗法进行文献综述.
- 分析涉及心肌中cGMP信号传递的分子机制.
- 对新型HF药物类别的临床试验数据的摘要.
主要成果:
- 新兴的药物类别,如SGLT2抑制剂,RNAI和sGC调节剂,在高频率治疗中显示出有效性.
- SGLT2 抑制剂在 HFrEF 和 HFpEF 两个方面都表现出有效性.
- 通过抵消有害的cAMP影响,cGMP信号通路为新型高频疗法提供了一个有希望的目标.
结论:
- 针对cGMP信号的新型药物类别代表了HF治疗的重大进步.
- 这些疗法有可能改善整个HF频谱的结果,包括HFpEF.
- 对cGMP途径的进一步研究可能会揭示心血管疾病的新治疗策略.
相关概念视频
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:26Heart Failure Drugs: Inotropic Agents
621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16